In-Office Procedures · Treatment
Low-Level Light Therapy (LLLT) for Dry Eye
LED-based photobiomodulation applied to the periocular area to reduce inflammation, stimulate meibomian gland function, and improve ocular surface health. TFOS DEWS III (2025) supports LLLT as an effective dry eye treatment modality, particularly in combination.
Key points
- Manufacturer direct through Equinox Ophthalmic and Celluma.
- LED photobiomodulation applied directly to the eyelids and periocular skin.
- Sub-thermal, so it carries no skin-tone limits, unlike IPL.
- Supported in TFOS DEWS III, often most effective combined with other treatments.
How it works
Low-level light therapy (LLLT), also called photobiomodulation (PBM), uses low-intensity LED light at specific wavelengths (typically 590 to 670 nm red light) applied directly to the closed eyelids or periocular skin. Unlike IPL, LLLT operates at sub-thermal intensities and does not cause tissue damage; instead it triggers photobiological responses in mitochondria that reduce local inflammation, stimulate cellular repair, and improve meibomian gland lipid secretion.
- Applied directly to the eyelids, no skin-tone contraindications unlike IPL
- Sessions typically 10 to 15 minutes
- Often performed in a series of 3 to 6 sessions, then maintenance as needed
- Can be combined with thermal pulsation, IPL, or lid debridement
Key devices
- Equinox (Equinox Ophthalmic), Ophthalmic-specific LLLT device designed for periocular application in the dry eye procedure suite. Equinox Ophthalmic
- Celluma, Multi-condition LED photobiomodulation panel used in ophthalmic and aesthetic practices. Celluma
Clinical evidence
- Prospective, randomized, observer-masked RCT, Nature Scientific Reports (2022), LLLT twice weekly for 3 weeks (6 sessions) produced statistically significant improvements in the primary endpoint (fluorescein corneal staining score) and secondary endpoints including lissamine green staining, Schirmer test scores, and upper meibography scores. TBUT and meibomian gland secretion showed improvement without reaching significance, suggesting stronger effects on aqueous and mucosal components. No serious adverse events. Nature Scientific Reports
- TFOS DEWS III Management and Therapy Report (2025), LLLT explicitly supported as an effective modality for dry eye and MGD, noted as often most effective when combined with other treatments. First time LLLT has been formally included in the global evidence-based dry eye guidelines at this level of evidence. American Journal of Ophthalmology
- Eye News DEWS III review (June 2026), DEWS III review confirms LLLT can be applied directly to the eyelids (unlike IPL) and is supported for MGD management, particularly in combination protocols. Eye News, DEWS III update
LLLT compared with IPL, key differences
| Feature | LLLT | OptiLight IPL |
|---|---|---|
| Application site | Directly on the closed eyelids | Below/around the eye on the cheek |
| Skin tone contraindication | None | Yes, not for Fitzpatrick V to VI without modification |
| Mechanism | Photobiomodulation, cellular repair | Photothermal, vessel ablation, anti-inflammatory |
| FDA clearance for dry eye/MGD | Not specifically cleared for DED indication | Yes, first and only IPL cleared for DED (2021) |
| TFOS DEWS III inclusion | Yes (2025) | Yes (2025) |
| Best for | Inflammatory DED; any skin tone; eyelid-directed treatment | MGD-driven evaporative dry eye; telangiectatic lid vessels |
Manufacturers
Sources are linked inline above. Device descriptions reference FDA clearance status, published peer-reviewed studies, and manufacturer data. Clinical outcomes are not a guarantee of individual results. Review full prescribing information, the IFU, and FDA clearance documentation for each device before use.
